Novartis: Cosentyx approved for hidrosadenitis suppurativa

(CercleFinance.com) - Novartis announces that the European Commission has approved Cosentyx for use in the EU in adult patients with moderate-to-severe active hidrosadenitis suppurativa who have had an inadequate response to conventional systemic therapy.


This European approval is based on robust phase III data showing that Cosentyx provided rapid symptom relief as early as week 4, with response rates continuing to improve for up to one year, with its known safety profile.

Hidrosadenitis suppurativa is a chronic inflammatory skin disease leading to painful and potentially disfiguring abscesses. Around 200,000 people in Europe are currently living with moderate-to-severe stages of the disease.


Copyright (c) 2023 CercleFinance.com. All rights reserved.